Aimmune Therapeutics Inc. (NASDAQ:AIMT) saw strong trading volume on Thursday . 997,169 shares were traded during mid-day trading, an increase of 549% from the previous session’s volume of 153,758 shares.The stock last traded at $14.00 and had previously closed at $12.92.

Several equities analysts have recently issued reports on the company. Wedbush reiterated an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Monday, June 13th. Bank of America Corp. reiterated a “buy” rating on shares of Aimmune Therapeutics in a research note on Monday, May 16th. Zacks Investment Research upgraded Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price objective for the company in a research note on Friday, May 20th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research note on Tuesday, May 17th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $33.40.

The firm’s market capitalization is $590.71 million. The firm has a 50 day moving average of $11.79 and a 200-day moving average of $13.80.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by $0.01. On average, equities analysts forecast that Aimmune Therapeutics Inc. will post ($1.71) EPS for the current year.

In other Aimmune Therapeutics news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 31st. The stock was sold at an average price of $15.23, for a total transaction of $3,655,200.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

A hedge fund recently raised its stake in Aimmune Therapeutics stock. RS Investment Management Co. LLC raised its position in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 12.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 804,143 shares of the company’s stock after buying an additional 88,180 shares during the period. RS Investment Management Co. LLC owned 1.90% of Aimmune Therapeutics worth $14,836,000 at the end of the most recent quarter.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.